Optimizing quality care for the oral vitamin K antagonists (VKAs)

Vittorio Pengo and Gentian Denas

Cardiology Clinic, Thrombosis Centre, University of Padua, Padua, Italy

Vitamin K antagonists (VKAs) have been the only oral anticoagulants for decades. The management of anticoagulant therapy with VKA is challenging because of the intricate pharmacological properties of these agents. The success of VKA therapy depends on the quality of treatment that is ensured through continuing comprehensive communication and education. The educational program should address important issues of the VKA therapy such as beginning of treatment, pharmacological, dietary, and drug–drug interactions, as well as treatment temporary suspension during surgical interventions or invasive maneuvers. In addition, the initial and continuing patient education is of imperative importance. A major role in the educational process may be addressed by patient associations. The quality of treatment is better reached if patients are followed in anticoagulation clinics. Moreover, a federation of anticoagulation clinics may improve patient care through regular meetings to update knowledge on VKA treatment. Learning objectives of this paper is to allow readers to correctly approach patients starting VKA treatment, recognize possible pitfalls of treatment, and provide adequate solutions.

Learning Objectives

- Initiate warfarin treatment and monitor patients in the follow-up period by modulating warfarin daily dose and performing bridging therapy in the occasion of surgery or invasive maneuvers
- Summarize the activities of an anticoagulation clinic in which patient education, clinical and laboratory monitoring, and drug–drug interaction are essential for a well-managed warfarin treatment

Introduction

Vitamin K antagonists (VKAs) have been the only oral anticoagulants for decades. Among them, warfarin is the most widely used agent, although others such as acenocoumarol, phenprocoumon, and indandione derivatives are also prescribed in some countries.

The indications of VKA therapy range from the prevention of stroke in patients with atrial fibrillation, prevention of recurrent thromboembolism in patients with deep vein thrombosis and pulmonary embolism, to the prevention of thrombosis in patients with valvular heart disease or prosthetic cardiac valves.

The management of anticoagulant therapy with VKA is challenging because of the intricate properties of these agents. VKA therapy is among the top drugs associated with serious adverse events and emergency department admissions. Therapeutic errors, such as inadequate prescription or administration, inappropriate monitoring, absence of treatment resulting from poor adherence, sector change (admission to or discharge from hospital), or undergoing surgery are the most common. These issues may have medico-legal implications ranging from the failure to prescribe anticoagulants when clinically indicated to inadequate monitoring of the therapy afterward. Despite the introduction of direct oral anticoagulants (DOACs), VKA therapy is still broadly used for other indications or in economical situations where DOACs cannot be afforded. Despite DOACs’ efficacy and safety profiles, their advantage comes less at sites with good international normalized ratio (INR) control, underlining the importance of local standards of care to affect the benefits of anticoagulation therapy. DOAC should not be seen as an absolute substitution of VKA, but as an extension of the antithrombotic armamentarium and the knowledge and education on VKA should not come less.

It is important to ensure continuing comprehensive communication and education concerning the beginning of treatment, pharmacological and dietary interactions, as well as suspension during surgical interventions or invasive maneuvers. In addition, the continuous patient education is of fundamental importance for a successful long-term therapy and requires permanent attention.

For these reasons, specialized structures have emerged in many countries (thrombosis centers or anticoagulation clinics), dedicated to monitoring VKA therapy. In this review, we will focus on the various issues of VKA therapy and provide adequate solutions.

Well-managed warfarin treatment

This high-quality anticoagulation management is poorly defined and difficult to assess. However, as with other chronic therapies, the ultimate goal is finding a safe balance between efficacy and safety. The achievement of a high-quality VKA therapy goes through a number of topics:

- Initial patient education
- Optimal laboratory control

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Off-label drug use: None disclosed.
that when applied, have been shown to improve the overall VKA therapy management call for patient educational programs, a mathematically transformed value converting the prothrombin time likely in low-income populations and related to perceived barriers, found to be predictors of nonadherence. Noncompliance is more isolation, interventional fragility, and information discomfort were adherent patients are more likely to be younger, male, and those

Rely on a center or doctor experienced in anticoagulant therapy

Reiterate proper intake of the drug and need for periodic checks

Outline of the most important drug interactions

Underline the risks related to treatment and treatment discontinuation

Explain the purpose of therapy in relation to patient’s disorder

Table 1. Elements of patient education

| Explain the purpose of therapy in relation to patient’s disorder |
| Underline the risks related to treatment and treatment discontinuation |
| Illustrate the duration of therapy |
| Explain what the term INR means and its relation with warfarin intake |
| Recommend a balanced diet emphasizing that no particular restrictions are necessary |
| Outline the most important drug interactions |
| Reiterate proper intake of the drug and need for periodic checks |
| Rely on a center or doctor experienced in anticoagulant therapy |

Point of care testing (POCT) for the self-determination of INR and self-management of anticoagulation is widely spread in some countries. In self-management, the patient takes an active part on determining the INR and deciding the dosage of VKAs. One review of 28 randomized trials found that self-monitoring and self-management halved thromboembolic events, but had a neutral effect on major bleeding. Despite the potentials of self-managed VKA therapy, it is still underused, especially in a setting of continuing VKA use in indications other than atrial fibrillation. It is still not well defined which subset of patients (in terms of indication for oral anticoagulation, age, comorbidity, social status, and training) might benefit more from self-management, but there have been attempts to identify the predictors of poor outcome useful to identify patients that might benefit from additional training, tight follow-up, or even management in anticoagulation clinics. Self-management has been used to different extent in different health realities depending on the legislation. In some countries, such as Italy, because of health policy constrains and medicolegal issues, the POCT is used mainly by health care personnel such as visiting nurses in confined to bed patients. In this way, the INR obtained are centralized to the thrombosis center where an experienced physician compiles the dosage calendar for the patient. External quality control for the POCTs as well as training are essential for a successful monitoring.

Initiation of anticoagulation (how we start treatment with warfarin)

The initiation of warfarin therapy is one of the most delicate aspects of the long-term management of VKA therapy. It requires an appropriate starting dose, frequent INR monitoring, and proper overlap with subcutaneous low-molecular-weight heparin (LMWH) if an immediate anticoagulant effect is required (such as in venous thromboembolism). The antithrombotic effect of VKA requires up to 5 or more days depending on the time required for complete reduction of the vitamin K–dependent coagulation factors (II, VII, IX, X). To achieve a rapid antithrombotic effect, bridging with LMWH (administered concurrently) for at least 5 days until the INR reaches therapeutic levels is necessary. Reaching therapeutic INR on the first 2 to 3 days is not indicative of an effective antithrombotic treatment. Different schemes for therapy initiation have been proposed when considering age and gender, indication for anticoagulation, and comorbidities. Initiating therapy with 5 mg warfarin, at least in hospitalized elderly patients, resulted in better outcomes in terms of excessive anticoagulation by day 4 or 5, than a 10-mg protocol. A 10-mg dose of warfarin resulted more effective in achieving more rapidly therapeutic range without excessive anticoagulation in patients with venous thromboembolism; however, there were few elderly patients included in the study. Lower initial starting doses have been shown as appropriate in patients with prosthetic heart valves. We adopt a 5-mg protocol for the initiation of warfarin therapy. On a previous observation, we found that a 10-mg protocol for 2 consecutive days resulted in excessive anticoagulation by day 3, especially in elderly patients. We therefore switched to a 5-mg protocol for 4 days that resulted in a more gradual increase of the INR values. Interestingly, we found a correlation between the INR
achieved on day 5 and the expected maintenance dose.\textsuperscript{26} Using the best-fit nonlinear regression curve, it was possible to calculate the weekly maintenance dose of warfarin based on INR on day 5 after 4 consecutive days on warfarin (5 mg/day). For example, if INR at day 5 is 1.5, then the weekly maintenance dose is 35 mg/week (5 mg/day).

The different response in terms of INR to a fixed dose of warfarin depends on several factors including genetics. Specifically, the involvement of CYP2C9 and VKORC1 in the warfarin pharmacology is known to influence individual warfarin response. Under these premises, several trials attempted to address the effect of genotype-guided warfarin dosing in improving warfarin dosing algorithms. Two randomized controlled trials generated different results. The Clarification of Optimal Anticoagulation Through Genetics trial\textsuperscript{37} compared an algorithm with clinical variables vs an algorithm with clinical variables and genotyping. The genetic algorithm did not significantly outperform the clinical variables algorithm. The European Pharmacogenetics of Anticoagulation Therapy–Warfarin trial,\textsuperscript{28} compared a standard fixed dose loading algorithm with a genotype-guided algorithm. The genetic-guided algorithm outperformed the fixed dose algorithm in terms of achieving a stable warfarin dose more quickly. Several factors might explain these contrasting results, including the comparator to genetic dosing.\textsuperscript{22,27} A fixed dose algorithm might perform worse than an algorithm, including clinical characteristics of the patients. We performed a study aimed to determine whether pharmacogenetics algorithm (based on CYP2C9- VKORC1-CYP4F2 polymorphism determination)\textsuperscript{30} was superior to our treatment scheme with standard fixed dosing.\textsuperscript{26} No significant differences were found in the number of out-of-range INR (INR < 2.0 or >3.0) (\(P = .79\)) and in the mean percentage of time spent in the therapeutic range (TTR) after 19 days in the pharmacogenetic (51.9%) and in the control arm (53.2%, \(P = .71\)).\textsuperscript{31} Genotype-guided warfarin dosing was not superior in overall anticoagulation control when compared with our standard pharmacodynamic method. With data in our hands, feasibility and cost-effectiveness\textsuperscript{32} does not justify an extensive use of genotype-based treatment algorithms. Their use might be confined in few specific situations.\textsuperscript{29,31}

Maintaining therapeutic anticoagulation and computer-aided prescription

After identification of best possible maintenance dose for optimal anticoagulation, it should be maintained within therapeutic range as much as possible. The percentage of time a patient’s INR is within the desired treatment range is measured by the TTR. TTR is the best recognized indicator of VKA anticoagulation quality. TTR has been shown to correlate with thrombosis recurrence and bleeding with VKA,\textsuperscript{33} and thus is indirectly a measure of the quality of anticoagulation. Once achieved, maintenance of optimal anticoagulation may not be straightforward given the fluctuation of INR even within the same individual. Predicting future dosage in a patient requires adequate training as well as a deep knowledge of VKA pharmacology. Dedicated software can aid in determining the correct warfarin dosage based on the present and past INR. This can make dosing of warfarin easier and more efficient especially in inexperienced hands.\textsuperscript{34} Computer-based dosing is reliable in most cases, although operator intervention should not be overlooked.\textsuperscript{35} The computer decision-aided support improves the laboratory quality of anticoagulant treatment, both during long-term maintenance and in the early, highly unstable phase of treatment, and significantly reduces the number of scheduled laboratory controls.\textsuperscript{36} Importantly, the computer-aided prescription makes easily available a calendar with the patient’s daily dose, thus improving compliance and reducing dosing errors and adverse events. It also stores INR history for the patient in a repository allowing for a readily available TTR calculation.

Supratherapeutic or subtherapeutic anticoagulation (high or low INR)

The problem of an excess anticoagulation during warfarin treatment is common in clinical practice. The main reasons for high or low INR are fluctuations in vitamin K dietary intake, interfering drugs (eg, amiodarone), incurring comorbidities, or poor compliance. Reversal of overanticoagulation can be achieved in several escalating ways, from up- or downregulation of the warfarin weekly dosage (for INR up to 4), to withholding anticoagulation and administration of vitamin K (for INR >5). No standardized regimen exists, and present regimens have not been individually compared. When vitamin K is used in nonemergency situations, small oral doses are recommended to avoid overcorrection and inducing warfarin resistance. In 2 registries, we found that oral doses of vitamin K of 2 to 3 mg are effective in correcting overanticoagulation.\textsuperscript{37,38} For patients with an INR between 5 and 10, in addition to omitting the day’s dose of warfarin, 2 mg of oral vitamin K are administered and INR values tested the following day.\textsuperscript{38} As shown in Figure 1A, the median (interquartile range) INR at presentation (day 0) fell to a safe median (interquartile range) the day after (day 1). We apply a different protocol to patients presenting with INR >10. In this case, in addition to omitting the day’s dose of warfarin, 3 mg of oral vitamin K are administered and INR tested the day after (Figure 1B). Results are reassuring because most patients had a safe INR on day 1.\textsuperscript{37}

Figure 1. Effect of administering (A) 2 or (B) 3 mg of vitamin K to reverse overanticoagulation in asymptomatic patients or those presenting with minimal bleeding. Reprinted by permission from (A) Springer Customer Service Center GmbH: Springer Nature (Denas G, et al, J Thromb Thrombolysis, 2009) and (B) Schattauer GmbH, Thieme Group (Denas G, et al, Thrombosis Haemostasis, 2009).
Moreover, the use of oral vitamin K in high-risk thromboembolic patients (such as those with mechanical heart valves (MHV) or recent cerebral ischemic events) warrants caution.

In case of low INR (0.5-1 below the lower limit), it is urgent to restore the correct anticoagulant regimen, particularly in high-risk patients (eg, those with mechanical prosthetic heart valves). Although the use of LMWH treatment is not evidence-based, in patients with mechanical prosthesis or mitral stenosis, we recommend its use at therapeutic doses for a limited amount of days (3-5). In the low-moderate risk patients, upregulation of warfarin dosage is enough to bring the INR back to therapeutic range in a short period. Thus, doubling the day’s dosage and modulating the following weekly dosage under a strict INR control might be sufficient to safely bring the INR back to therapeutic level. Because the most common cause of subtherapeutic INR is poor adherence to treatment, a conversation face-to-face to remind the importance of correct intake of warfarin is also advisable.

**Bridging anticoagulation**

This term defines the introduction of a short-acting anticoagulant (LMWH) during warfarin interruption for a 10- to 12-day period when the INR is not within the therapeutic range to minimize the risk of thromboembolism. Several prospective cohort studies were performed looking at thromboembolic and bleeding events during bridging therapy either at therapeutic or subtherapeutic regimens.

In a multicenter prospective inception cohort management study, we assessed the efficacy and safety of an individualized bridging protocol applied to outpatients. An oral anticoagulant, warfarin or acenocoumarol, was stopped 5 days before the procedure and LMWH was started 3 to 4 days (in case of warfarin or acenocoumarol, respectively) before surgery. Anticoagulants were not administered at the day of surgery. LMWH was started the day after surgery with a dosage of 70 anti-factor Xa U/kg twice daily in high-thromboembolic-risk patients and prophylactic once-daily doses in moderate- to low-risk patients. Oral anticoagulation was also resumed the day after the procedure with a 50% increased dosage for 2 days and maintenance doses afterward. As shown in Figure 2, INR levels declined to intervention-safe levels on day 0 and recovered correctly after warfarin reintroduction. The bridging protocol

![Figure 2. Declining of INR values during the 5 days of warfarin suspension before surgery/intervention. Different colors denote different warfarin indications. The orange line show the mean INR values for all indications. Warfarin was resumed at a 50% increased maintenance dose for 2 days starting the first or second day after surgery/intervention. Therapeutic INR values were usually reached after 1 week. AF, atrial fibrillation; VTE, venous thrombosis.](image-url)

### Table 2. Commonly used drugs and their effect on INR

| Drugs                                           | Effect on INR |
|-------------------------------------------------|---------------|
| Amiodarone                                       | Increases     |
| Antibiotics: ciprofloxacin, metronidazole, fluconazole, voriconazole, isoniazid, clarithromycin, erythromycin | Increases     |
| Rifampcin                                        | Lowers        |
| Sertraline, fluoxetine                           | Increases     |
| Carbamazepine, phenobarbital                     | Lowers        |
| Lovastatin, fluvastatin                          | Increases     |
| Alternative remedies: St John’s wort, charbroiled food | Lowers        |
appeared feasible, effective, and safe for most patients. It showed that tailoring the bridging regimen to thromboembolic risk and using subtherapeutic doses (70%) of LMWH was effective and safe. To conclusively establish its safety in patients with mechanical prosthetic valves, we performed a further cohort study.42 This study included bearers of MHV in the mitral position, or in the aortic position associated with risk factors. We found that bridging with subtherapeutic doses of LMWH in high-risk MHV patients is effective, although complicated by nonfatal major bleeding. Whenever major bleeding occurred, it was related to the surgical setting or to surgery’s bleeding risk.43 A recent clinical trial compared bridging therapy with heparin with a strategy of continued warfarin treatment at the time of pacemaker or implantable cardioverter–defibrillator surgery (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial) and showed that warfarin continuation markedly reduced the incidence of clinically significant device-pocket hematoma.43 The Effectiveness of Bridging Anticoagulation for Surgery study randomized patients with atrial fibrillation undergoing elective operation or invasive maneuvers to bridging therapy (dalteparin 100 IU per kg twice daily) or placebo.44 Forgoing bridging anticoagulation was noninferior to perioperative bridging with LMWH for the prevention of arterial thromboembolism and decreased the risk of major bleeding; however, most patients were at low thromboembolic risk. The latest guidelines of American College of Chest Physicians suggest (grade 2C) the use of bridging with LMWH only in patients with a mechanical heart valve, atrial fibrillation, or venous thrombosis at high risk for thromboembolism.45

High-level evidence on bridging has started to build for low thromboembolic risk patients and low bleeding risk procedures. Oral anticoagulation should not be interrupted for low risk procedures. Patients at high thromboembolic risk should undergo bridging, especially if at low bleeding risk. In this setting, subtherapeutic doses of LMWH were shown to be safe and effective. A tailored approach should be reserved for each patient balancing thromboembolic and bleeding risk.

Management of intake or suspension of interfering drugs

Drug–drug interaction using warfarin are frequently reported in the literature.46,47 Although clinically relevant drug interactions (Table 2) are few,48 amiodarone, a drug widely used in patients with atrial fibrillation, determines an excess of anticoagulation that requires a reduction of the amount of warfarin of 25% to 50%. The opposite happens at the suspension that should be carefully monitored given the long half-life of this drug (90 days). Other commonly used medications that interfere with warfarin therapy are azole antibiotics, macrolides,
quinolones, and nonsteroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors, selective serotonin reuptake inhibitors, omeprazole, fluorouracil, and rifampicin. Whenever possible, coadministration with these agents should be avoided or INRs should be closely monitored.

**Improvement of quality of anticoagulation across anticoagulation clinics**

VKA have been used for more than 60 years. Because of the complexity of the therapy, efforts have been made worldwide to improve management. The introduction of anticoagulation clinics has had a positive impact on oral anticoagulation management, and represent the best management model. Anticoagulation clinics have a central role in determining appropriate indications for anticoagulation, initiating and monitoring treatment through laboratory tests (INR), determinations of time intervals for testing, and dosage modifications, providing indications for therapy interruptions and bridging therapy. They also have a central role on education of patients and health care personnel. In Italy, the Italian Federation of Centers for surveillance of antithrombotic treatments annually publishes updated recommendations on oral anticoagulant treatment, including the management of specific clinical situations, and invites members to participate in an educational program aimed at providing accreditation for the anticoagulation center. This educational effort has been translated to overall satisfactory levels of TTR control across the country (Figure 3). The satisfactory levels of quality of anticoagulation with VKA gives very good results in terms of stroke prevention in atrial fibrillation even when compared with the DOAC registration studies (Figure 4). However, even under the premises of good TTR, DOAC maintain the superior safety profile halving the incidence of intracranial bleeding.

In the Internet era, efforts have been made worldwide to provide patients and health care personnel with updated knowledge and tools on oral anticoagulation treatment and self-management.

**Consensus (hospital- or regional-based) treatment decisional pathways**

The quality of treatment improves through homogenous management of the therapy. A robust common pathway for outpatient care offers clear, evidence-based guidance for the management of patients receiving VKA. It includes the correct identification, diagnosis, and treatment of patients followed in an outpatient setting providing references to health care personnel not directly involved in this setting. A common pathway avoids misunderstanding among all specialists involved in the patient care. Consensus on VKA treatment modalities should be reached at hospital and ideally at regional level.

**Conclusions**

Oral anticoagulation therapy with VKA remains the mainstay therapy for the prevention and treatment of thromboembolism in certain indications and socioeconomic settings. Because the management of VKA treatment is complex, its success heavily relies on the quality of treatment. An optimal quality of treatment with VKA involves initiating appropriate therapy, maintaining therapeutic anticoagulation measured through TTR, monitoring anticoagulation at the appropriate frequency, managing perioperative dosing, and managing nontherapeutic INR, which is best performed in anticoagulation centers. Optimal quality of treatment also involves continuous patient education and extensive communication.

**References**

1. Pengo V, Pegoraro C, Cucchini U, Illiceto S. Worldwide management of oral anticoagulant therapy: the ISAM study. *J Thromb Thrombolysis*. 2006;21(1):73-77.

2. Budnitz DS, Pollock DA, Weidenbach KN, Mendelson AH, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. *JAMA*. 2006;296(15):1858-1866.

3. Bennett CL, Tique CC, Angelotta C, McKoy JM, Edwards BJ. Adverse effects of drugs used to treat hematologic malignancies: surveillance efforts from the research on adverse drug events and reports project. *Semin Thromb Hemost*. 2007;33(4):365-372.

4. Henriksen JN, Nielsen LP, Hellebæk A, Poulsen BK. Medication errors involving anticoagulants: data from the Danish patient safety database. *Pharmacol Res Perspect*. 2017;5(3):e00307.

5. El-Helou N, Al-Hajje A, Ajrouche R, et al. Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance. *Vasc Health Risk Manag*. 2013;9:81-88.

6. Wallentin L, Yusuf S, Ezekowitz MD, et al; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. *Lancet*. 2010;376(9745):975-983.

7. Phillips KW, Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. *Expert Rev Cardiovasc Ther*. 2008;6(1):57-70.

8. World Health Organization. Therapeutic patient education. Continuing education programmes for health care providers in the field of prevention of chronic diseases. Available at: [http://apps.who.int/nr/eb/ebcm/handle/10665/108151/E63674.pdf?sequence=1&isAllowed=y](http://apps.who.int/nr/eb/ebcm/handle/10665/108151/E63674.pdf?sequence=1&isAllowed=y). Accessed 27 September 2018.

9. Cruess DG, Localio AR, Platt AB, et al. Patient attitudinal and behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics. *Int J Behav Med*. 2010;17(1):33-42.

10. Orensky IA, Holdford DA. Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic. *Pharmacotherapy*. 2005;25(12):1801-1808.

11. Arnsten JH, Gelfand JM, Singer DE. Determinants of compliance with anticoagulation: A case-control study. *Am J Med*. 1997;103(1):11-17.

12. Palareti G, Legnani C, Guazzaloca G, et al; ad hoc Study Group of the Italian Federation of Anticoagulation Clinics. Risks factors for highly unstable response to oral anticoagulation: a case-control study. *Br J Haematol*. 2005;129(1):72-78.

13. Pamboukian SV, Nisar I, Patel S, et al. Factors associated with non-adherence to therapy with warfarin in a population of chronic heart failure patients. *Clin Cardiol*. 2008;31(1):30-34.

14. Tosetto A, Manotti C, Marongiu F; Italian Federation of Anticoagulation Clinics (FCSA) clinical quality study group. Center-related determinants of VKA anticoagulation quality: a prospective, multicenter evaluation. *PLoS One*. 2015;10(12):e0144314.

15. Heneghan CJ, Garcia-Alamino JM, Spencer EA, et al. Self-monitoring and self-management of oral anticoagulation. *Cochrane Database Syst Rev*. 2016;7(CD003839).

16. Christensen TD, Groe EL, Nielsen PB, Larsen TB. Self-managed oral anticoagulant therapy: a call for implementation. *Expert Rev Cardiovasc Ther*. 2016;14(3):255-257.

17. Garcia-Alamino JM, Ward AM, Alonso-Coello P, et al. Self-monitoring and self-management of oral anticoagulation. *Cochrane Database Syst Rev*. 2010; (4):CD003839.

18. Schaefer C, Willemin WA, Kessels A, Jacobson A, Nagler M. Predictors of anticoagulation quality in 15 834 patients performing patient self-management of oral anticoagulation with vitamin K antagonists in real-life practice: a survey of the International Self-Monitoring

**Correspondence**

Vittorio Pengo, Cardiology Clinic, Department of Cardiac, Thoracic, and Vascular Sciences, Padua University Hospital, Via Giustiniani 2, 35121 Padua, Italy; e-mail: vittorio.pengo@unipd.it.
332 American Society of Hematology

Association of Orally Anticoagulated Patients. *Br J Haematol.* 2016;175(4):677-685.

19. Barcellona D, Fenu L, Cornacchini S, Marongiu F. Point-of-care (POCT) prothrombin time monitors: is a periodical control of their performance useful? *Thromb Res.* 2009;123(5):773-779.

20. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance-dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. *Chest.* 2005;127(6):2049-2056.

21. Ageno W, Turpie AG, Steidl L, et al. Comparison of a daily fixed 2.5-mg warfarin dose with a 5-mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement. *Am J Cardiol.* 2001;88(1):40-44.

22. Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. *Ann Intern Med.* 2003;138(9):714-719.

23. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. *Ann Intern Med.* 1997;126(2):133-136.

24. Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. *Arch Intern Med.* 1999;159(1):46-48.

25. Prego V, Zasso A, Barbero F, Biasiolo A, Rampazzo P, Brocco T. Initiation of warfarin treatment in outpatients with nonthrombotic atrial fibrillation: a scheme for early indication of maintenance dose. *Clin Appl Thromb Hemost.* 1998;4(4):274-276.

26. Prego V, Biasiolo A, Pegoraro C. A simple scheme to initiate oral anticoagulant treatment in outpatients with nonthrombotic atrial fibrillation. *Am J Cardiol.* 2001;88(10):1214-1216.

27. Kimmel SE, French B, Kasner SE, et al; COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. *N Engl J Med.* 2013;369(24):2283-2293.

28. Pirmohamed M, Burnside G, Eriksson N, et al; EU-PACT Group. A randomized trial of genotype-guided dosing of warfarin. *N Engl J Med.* 2013;369(24):2294-2303.

29. Mega JL, Giugliano RP. Genotype-guided dosing of warfarin. *Clin Chem.* 2014;60(7):920-922.

30. Zambon CF, Pengo V, Fadini R, et al. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. *Pharmacogenomics.* 2011;12(1):15-25.

31. Pengo V, Zambon CF, Fogar P, et al. A randomized trial of pharmacogenetic warfarin dosing in naïve patients with non-valvar atrial fibrillation. *PloS One.* 2015;10(12):e0145318.

32. Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. *Circ Cardiovasc Qual Outc.* 2009;2(5):429-436.

33. Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. *J Thromb Thrombolysis.* 2003;15(3):213-216.

34. Nieuwlaat R, Hubers LM, Sypopoulos AC, et al. Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. *Thromb Haemost.* 2012;108(6):1228-1235.

35. Grzymala-Lubanski B, Själander S, Renlund H, Svensson PJ, Själander A. Computer aided warfarin dosing in the Swedish national quality registry AuriculA - algorithmic suggestions are performing better than manually changed doses. *Thromb Res.* 2013;131(2):130-134.

36. Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori AG. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated Program for Oral Anticoagulant Treatment). *Haematologica.* 2001;86(10):1060-1070.

37. Denas G, Cucchinì U, Iliceto S, Pengo V. An oral vitamin K protocol to reverse over-anticoagulation in patients presenting with an international normalised ratio above 10.0. *Thromb Haemost.* 2009;101(2):410-411.

38. Denas G, Marzot F, Offelli P, et al. Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases. *J Thromb Thrombolysis.* 2009;27(3):340-347.

39. Torn M, Canneigieter SC, Bolien WL, van der Meer FJ, van der Wall EE, Rosendaal FR. Optimal level of oral anticoagulant therapy for the preven- tion of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4,022 patients. *Arch Intern Med.* 2009;169(13):1203-1209.

40. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Anti- thrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(suppl 2):e152S-e184S.

41. Pengo V, Cucchinì U, Denas G, et al; Italian Federation of Centers for the Diagnosis of Thrombosis and Management of Antithrombotic Therapies (FCSA). Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. *Circulation.* 2009;119(22):2920-2927.

42. Denas G, Desta S, Quintavalla R, et al. A bridging protocol in high-thrombotic risk mechanical valve bearers undergoing surgery or invasive procedures. *J Am Coll Cardiol.* 2016;68(24):2714-2715.

43. Birnie DH, Healey JS, Wells GA, et al; BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. *N Engl J Med.* 2013;368(22):2084-2093.

44. Douketis JD, Sypopoulos AC, Kaatz S, et al; BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation. *N Engl J Med.* 2015;373(9):823-833.

45. Douketis JD, Sypopoulos AC, Spencer FA, et al. Perioperative man agement of antithrombotic therapy: Anti- thrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(suppl 2):e326S-e350S.

46. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. *Arch Intern Med.* 2005;165(10):1095-1106.

47. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. *Ann Intern Med.* 1994;121(9):676-683.

48. Ageno W, Gallus AS, Witkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Anti-thrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(suppl 2):e445S-e488S.

49. Testa S, Puolletti O, Zimmermann A, Bassi L, Zambelli S, Cancellieri E. The role of anticoagulation clinics in the era of new oral anticoagulants. *Thromb Res.* 2012;120(2):835-856.

50. Antonucci E, Poli D, Tosetto A, et al; START-Register. The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. *Thromb Haemost.* 2012;108(6):1228-1235.

51. Palareti G, Antonucci E, Migliaccio L, et al; centers participating in the FCSA-START-Register (The ISCOAT 2016 study: Italian Study on Complications of Oral Anticoagulant Therapy-2016). Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. *Intern Emerg Med.* 2017;12(8):1109-1119.

52. Denas G, Gennaro N, Ferroni E, et al. Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvar atrial fibrillation: propensity score matched cohort study. *Int J Cardiol.* 2017;249:198-203.

53. Arianna Anticoagulation Foundation. Who we are. Available at https://www.anticoagulazione.it/index.php/who-we-are. Accessed 27 September 2018.

54. International Self-Monitoring Association of Oral Anticoagulated Patients - ISMAAP. Home page. Available at: https://www.ismaap.org/welcome-to-ismaap/. Accessed 27 September 2018.

55. Anticoagulation Centers of Excellence. Welcome to anticoagulation centers of excellence. Available at: http://excellence.afcforum.org/index.php. Accessed 27 September 2018.